BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8968218)

  • 1. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies.
    Sanders DB
    Ann Neurol; 1995 May; 37 Suppl 1():S63-73. PubMed ID: 8968218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
    Honnorat J
    Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
    Vincent A; Lang B; Newsom-Davis J
    Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    Schoser B; Eymard B; Datt J; Mantegazza R
    J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
    Kitanosono H; Shiraishi H; Motomura M
    Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
    Flink MT; Atchison WD
    J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lambert-Eaton myasthenic syndrome in childhood.
    Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lambert Eaton myasthenic syndrome.
    Petty R
    Pract Neurol; 2007 Aug; 7(4):265-7. PubMed ID: 17636143
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism.
    Gable KL; Massey JM
    Semin Neurol; 2015 Aug; 35(4):340-6. PubMed ID: 26502758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lambert-Eaton Myasthenic Syndrome.
    Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
    Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
    Sakai W; Nakane S; Matsuo H
    Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
    Mason WP; Graus F; Lang B; Honnorat J; Delattre JY; Valldeoriola F; Antoine JC; Rosenblum MK; Rosenfeld MR; Newsom-Davis J; Posner JB; Dalmau J
    Brain; 1997 Aug; 120 ( Pt 8)():1279-300. PubMed ID: 9278623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
    Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
    Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
    Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
    Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of Lambert-Eaton myasthenic syndrome immunoglobulin for nerve terminal calcium channels.
    Hewett SJ; Atchison WD
    Brain Res; 1992 Dec; 599(2):324-32. PubMed ID: 1363289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.